Clinical trial of bacampicillin in acute bacterial infections.
A clinical trial of bacampicillin was carried out in 20 patients. The antibiotic was found to be effective in acute lobar pneumonia, pyogenic meningitis, acute and chronic bronchitis, acute pharyngitis, acute tonsillitis, cellulitis, furunculosis, and pyomyositis caused by such ampicillin-sensitive organisms as Neisseria meningitidis, Diplococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pyogenes, Klebsiella pneumoniae, and Escherichia coli. Rash in three patients was the only side effect encountered. It is concluded that while bacampicillin may have overcome some of the disadvantages of ampicillin, it retains its main attributes and some shortcomings.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D002481:Cellulitis / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D005667:Furunculosis / Q000188:drug therapy; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D008875:Middle Aged; D010612:Pharyngitis / Q000188:drug therapy; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy
D000667:Ampicillin; C011674:bacampicillin